vs
Side-by-side financial comparison of Context Therapeutics Inc. (CNTX) and GAXOS.AI INC. (GXAI). Click either name above to swap in a different company.
Context Therapeutics Inc. is the larger business by last-quarter revenue ($1.2M vs $1.2M, roughly 1.0× GAXOS.AI INC.). GAXOS.AI INC. runs the higher net margin — -77.2% vs -1403.9%, a 1326.6% gap on every dollar of revenue. On growth, GAXOS.AI INC. posted the faster year-over-year revenue change (94996.3% vs 328.2%).
Context Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing innovative targeted therapies for hormone-driven cancers. Its core pipeline includes candidates for breast, ovarian and other gynecologic malignancies, primarily serving oncology patient populations across North America and Europe.
CNTX vs GXAI — Head-to-Head
Income Statement — Q3 FY2024 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.2M | $1.2M |
| Net Profit | $-17.5M | $-957.9K |
| Gross Margin | — | — |
| Operating Margin | -1503.7% | -99.0% |
| Net Margin | -1403.9% | -77.2% |
| Revenue YoY | 328.2% | 94996.3% |
| Net Profit YoY | -197.2% | -15.1% |
| EPS (diluted) | $-0.22 | $-0.13 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $1.2M | ||
| Q3 25 | — | $498.3K | ||
| Q2 25 | — | $171.0K | ||
| Q3 24 | $1.2M | — | ||
| Q2 24 | $840.1K | $0 | ||
| Q4 23 | $224.7K | — | ||
| Q3 23 | $290.4K | — | ||
| Q2 23 | $293.3K | — |
| Q4 25 | — | $-957.9K | ||
| Q3 25 | — | $-1.0M | ||
| Q2 25 | — | $-749.4K | ||
| Q3 24 | $-17.5M | — | ||
| Q2 24 | $-2.3M | $-809.2K | ||
| Q4 23 | $-6.8M | — | ||
| Q3 23 | $-5.9M | — | ||
| Q2 23 | $-5.0M | — |
| Q4 25 | — | -99.0% | ||
| Q3 25 | — | -263.9% | ||
| Q2 25 | — | -574.8% | ||
| Q3 24 | -1503.7% | — | ||
| Q2 24 | -367.6% | — | ||
| Q4 23 | -3085.3% | — | ||
| Q3 23 | -2128.0% | — | ||
| Q2 23 | -1804.6% | — |
| Q4 25 | — | -77.2% | ||
| Q3 25 | — | -201.0% | ||
| Q2 25 | — | -438.3% | ||
| Q3 24 | -1403.9% | — | ||
| Q2 24 | -268.3% | — | ||
| Q4 23 | -3012.6% | — | ||
| Q3 23 | -2022.7% | — | ||
| Q2 23 | -1708.8% | — |
| Q4 25 | — | $-0.13 | ||
| Q3 25 | — | $-0.14 | ||
| Q2 25 | — | $-0.11 | ||
| Q3 24 | $-0.22 | — | ||
| Q2 24 | $-0.04 | $-0.72 | ||
| Q4 23 | $-0.42 | — | ||
| Q3 23 | $-0.37 | — | ||
| Q2 23 | $-0.31 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $84.8M | $840.5K |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $83.9M | $13.1M |
| Total Assets | $86.3M | $13.4M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $840.5K | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q3 24 | $84.8M | — | ||
| Q2 24 | $101.5M | $4.5M | ||
| Q4 23 | $14.4M | — | ||
| Q3 23 | $21.7M | — | ||
| Q2 23 | $25.1M | — |
| Q4 25 | — | $13.1M | ||
| Q3 25 | — | $14.1M | ||
| Q2 25 | — | $15.0M | ||
| Q3 24 | $83.9M | — | ||
| Q2 24 | $101.1M | $4.7M | ||
| Q4 23 | $11.9M | — | ||
| Q3 23 | $18.4M | — | ||
| Q2 23 | $24.0M | — |
| Q4 25 | — | $13.4M | ||
| Q3 25 | — | $14.3M | ||
| Q2 25 | — | $15.4M | ||
| Q3 24 | $86.3M | — | ||
| Q2 24 | $102.7M | $5.1M | ||
| Q4 23 | $16.1M | — | ||
| Q3 23 | $23.0M | — | ||
| Q2 23 | $27.8M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-1.9M | $-733.1K |
| Free Cash FlowOCF − Capex | $-1.9M | — |
| FCF MarginFCF / Revenue | -156.0% | — |
| Capex IntensityCapex / Revenue | 0.6% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-733.1K | ||
| Q3 25 | — | $-1.1M | ||
| Q2 25 | — | $-716.9K | ||
| Q3 24 | $-1.9M | — | ||
| Q2 24 | $-3.4M | $-738.5K | ||
| Q4 23 | $-7.2M | — | ||
| Q3 23 | $-3.5M | — | ||
| Q2 23 | $-4.6M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q3 24 | $-1.9M | — | ||
| Q2 24 | — | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q3 24 | -156.0% | — | ||
| Q2 24 | — | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q3 24 | 0.6% | — | ||
| Q2 24 | 0.0% | — | ||
| Q4 23 | 0.0% | — | ||
| Q3 23 | 0.0% | — | ||
| Q2 23 | 0.0% | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
